Rationale: Modulating the low-grade chronic inflammation in chronic obstructive pulmonary disease remains challenging. Clarithromycin (CAM), a macrolide antibiotic, reportedly ameliorates chronic inflammation via mechanisms independent of its antibacterial activity. Objectives: The aim of this study was to examine whether CAM can prevent or reduce emphysema induced by chronic cigarette smoke exposure. Methods: Mice were exposed to cigarette smoke daily for 6 months and treated with orally administered CAM at doses of 25 to 100 mg/kg twice a day throughout the course of the experiment to test the preventive effects. The administration of CAM at 50 or 100 mg/kg was performed during the second half of a 6-month exposure period to assess the therapeutic effects. Histologic analysis was performed to evaluate the effect of CAM. Measurements and Main Results: CAM treatment for 6 months decreased airspace enlargement and the destruction of the alveolar walls and impaired the accumulation of macrophages in bronchoalveolar lavage fluid in a dose-related fashion. The administration of clarithromycin at 100 mg/kg in the therapeutic protocol reduced emphysema compared with the smoke-exposed group without treatment. An immunohistologic analysis revealed that CAM reduced the number of F4/80-positive macrophages in the lung parenchyma.
Chronic obstructive pulmonary disease (COPD) is a rapidly increasing global health problem. The numbers of patients with COPD in the United States and Japan are estimated to be over 18 million and 5 million, respectively (1, 2) . The Global Initiative for Chronic Obstructive Lung Disease guidelines define COPD as a disease associated with an abnormal inflammatory response of the lungs in response to noxious particles and gases such as cigarette smoke.
During the past decade, various inflammatory molecules have been reported to be involved in this process (3, 4) . Chemokines and other chemoattractants, such as IL-8, MCP-1, and LTB4, enhance the accumulation of inflammatory cells, including macrophages and neutrophils, in the lungs. Macrophages activated by cigarette smoke produce reactive oxygen species and many cytokines, such as tumor necrosis factor (TNF)-a and IL-6. Inflammatory-activated macrophages and neutrophils also release proteinases, including elastases, matrix metalloproteinase (MMP)-9, and MMP-12 (5) (6) (7) (8) (9) . These proteinases are involved in the degradation of extracellular matrix components, including elastin, and enhance emphysema.
The current pharmacologic therapy for COPD is supportive and palliative, such as the use of bronchodilators. Approaches aimed at modulating the low-grade chronic inflammation that is characteristic of COPD remain challenging. Antiinflammatory steroids are used often in patients with COPD with acute exacerbation, but steroids are not effective for reducing chronic inflammation in COPD. Phosphodiesterase type 4 inhibitors are expected to be useful modulators of lung inflammation (10, 11) . However, the long-term clinical benefits of these drugs remain uncertain (12) . Selective inhibitors against chemokine receptors, proteases, and signaling molecules, such as IKKb and MAP kinase p38, have been developed and applied in clinical trials for patients with COPD (13) (14) (15) (16) (17) . However, the clinical efficacy of these drugs remains unproven.
Clarithromycin (CAM) is a 14-membered ring macrolide antibiotic that has been prescribed for the treatment of various respiratory infections. In addition to its antibiotic activity, CAM reportedly modulates the immune system and has been shown to ameliorate chronic inflammation in various animal models by impairing the expression of proinflammatory molecules, such as cytokines, adhesion molecules, and lipid mediators (18) (19) (20) . Lowdose, long-term, 14-membered ring macrolide therapy has been reported to be effective for treating patients with diffuse pan-bronchiolitis or bronchiectasis via mechanisms independent of its antibacterial activity (21) .
In this study, we evaluated the efficacy of CAM in emphysema using a mouse model for cigarette smoke exposure. CAM exerted preventive or therapeutic effects on emphysema by reducing the accumulation of inflammatory cells in the lung.
METHODS
Animal Model for Cigarette Smoke Exposure C57 BL/6 female mice (12 wk of age) were subjected to two unfiltered cigarettes (research cigarettes obtained from the University of Kentucky) per day, 6 days/week for 6 months, as previously described (9, 22) . All animals were housed within a pathogen-free sterile barrier facility, and no infections were identified in this colony during the examination period.
Dosing
Clarithromycin (Taisho Pharmaceutical Co., Ltd., Saitama, Japan) was orally administered at doses of 25, 50, or 100 mg/kg. The dosing was performed twice a day throughout the course of the experiment to test the preventive effects of CAM. To assess the therapeutic effect of CAM on emphysema, the administration of CAM at 50 or 100 mg/kg was performed twice a day during the second half of a 6-month exposure period in a second experiment protocol. The area under the curve value indicated that a dose of 25 to 100 mg/kg in mice is comparable to clinically achievable levels in humans (see the online supplement for details).
Morphometry and Cell Counting in Bronchoalveolar Lavage Fluid
The right lung was inflated by instilling neutral-buffered 10% formalin to 25 cm H 2 O for 15 minutes. The right lung was ligated, removed, and fixed for 48 hours. Mid-sagittal sections stained with hematoxylin and eosin were used to calculate the mean linear intercept (Lm) and the destructive index (DI) as previously described (22, 23 ). An average point count from 10 random fields was calculated at a magnification of 2003. The left lung was used to count the cells in the bronchoalveolar lavage fluid (BALF) as previously described (9) (see online supplement for details).
Lung Compliance Assessment
Twenty-four hours after the last smoke exposure, the mice were anesthetized using avertin. The trachea cannula was attached to a FlexiVent (Scireq, Montreal, Quebec, Canada) to analyze lung function. Pressure-volume curves were generated, and the static lung compliance was calculated using FlexiVent software.
Immunohistochemical Staining for F4/80 in Lung Alveolar Macrophages
Deparaffinized sections of lung were incubated with 20 mg/mL rat antimouse F4/80 antibody (MCAP497; Serotec, Oxford, Oxon, UK) and were stained using an indirect immunofluorescence method. F4/80-positive macrophages were represented as the average count from 30 different high-powered fields per slide that have been corrected for millimeter of the alveolar wall using the morphometric data (see online supplement for details).
In Vitro Assay of Matrix Metalloproteinase-9 Expression
Macrophages were harvested from the peritoneal cavities of mice that had been treated with 1 mg of Zymosan A (Sigma, Brooklyn, NY) for 3 days. CAM was added at a final concentration of 1.25, 5, or 20 mM 1 hour before TNF-a stimulation. Real-time PCR for murine MMP-9 was performed using a murine MMP-9 TaqMAN probe according to the manufacturer's protocol (see the online supplement for details).
Statistical Analysis
Data are expressed as mean 6 SEM unless otherwise indicated. Statistical significance was determined using the Student t test or one-way ANOVA; P , 0.05 was considered statistically significant (see online supplement for details).
RESULTS

Effect of CAM on Emphysema Induced by Cigarette Smoke in a Preventive Protocol
To address whether CAM, a 14-membered ring macrolide antibiotic, could prevent emphysema, we exposed mice to cigarette smoke daily for 6 months as described previously (22) and administered CAM at doses of 25 to 100 mg/kg twice daily throughout the course of the 6-month experiment. Histologic analysis demonstrated that the lungs of the mice exposed to smoke and treated with CAM at doses of 50 mg/kg were distinguishable from the lungs of the mice exposed to smoke alone ( Figure 1A-1C) . Therefore, we examined the enlargement of the airspaces by quantifying the Lm and the destruction of the alveolar walls by measuring the DI to quantify the severity of the emphysema (Table 1 ). In addition, we counted the macrophages in BALF obtained at the end of the 6-month experiment (Table 1) . Six months of smoke exposure increased the Lm by 20% and the DI by 215% (non-smoke versus smoke: both P , 0.0001) and the accumulation of macrophages in BALF by 2.3-fold (non-smoke versus smoke: P , 0.0001) in the preventive experiment. The administration of CAM at doses of 25 mg/kg for 6 months partially inhibited the increase in the DI (vehicle group 5 45 6 3.7; 25 mg/kg treatment group 5 22.5 6 2.5; P , 0.0001) and the accumulation of macrophages into the BALF (vehicle group 5 56.5 6 4.39 3 10 3 ; 25 mg/kg treatment group 5 38.3 6 3.66 3 10 3 ; P 5 0.0009), and treatment with 25 mg/kg of CAM tended to decrease the Lm, although the difference was not statistically significant (vehicle group 5 38.7 6 0.8; 25 mg/kg treatment group 5 35.5 6 1.4; P 5 0.11). The administration of 50 mg/kg or 100 mg/kg of CAM Figure 1 . Clarithromycin (CAM) protects against emphysema induced by cigarette smoke in mice. The lungs were inflated using neutral-buffered 10% formalin and embedded. Hematoxylin and eosin (H&E) staining was used for the morphologic analysis. Representative H&E sections are presented for non-smoke-exposed mice (A), mice exposed to smoke for 6 months (B), and smoke-exposed mice treated with CAM at 50 mg/kg (C ). Scale bar, 100 mm.
prevented emphysema and the accumulation of macrophages in BALF, as indicated by significant decreases in the Lm, DI, and the number of macrophages in BALF. Taken together, these results demonstrate that CAM treatment prevented smoke-induced emphysema in a dose-related fashion in the mice model.
Prevention of Lung Inflammation Induced by Cigarette Smoke in a Therapeutic Protocol
We assessed the therapeutic effect of CAM on emphysema. Initially, we examined the time course of the accumulation of macrophages in BALF to determine the onset of lung inflammation in this model. After 1 week and 1 month of exposure, the numbers of macrophages in BALF samples obtained from smoke-exposed and control mice were not significantly different ( Figure 2) . At 3 months, we did not observe a significant histologic difference between the non-smoke-exposed and the smokeexposed mice. However, after 3 and 6 months of exposure, the cell numbers in the smoke-exposed group increased significantly by 1.6-fold (P , 0.01) and 2.1-fold (P , 0.001), respectively, compared with that in the control group (Figure 2 ), indicating that the onset and chronic progression of lung inflammation had occurred after 3 months of exposure in this animal model. We therefore administered CAM at a concentration of 50 or 100 mg/ kg twice daily for only the last 3 months of the exposure period (Treatments 4 and 5 in Table 2 ) in the therapeutic protocol. We also treated some mice with 50 mg/kg of CAM (Treatment 3 in Table 2 ) throughout the 6-month smoke-exposure period, as in the preventive protocol, to check the reproducibility of our findings. We discontinued smoke exposure after 3 months in one group to observe the effects of smoking cessation. We obtained reproducible results regarding the preventive effect of CAM at concentrations of 50 mg/kg on smoke-induced emphysema, as indicated by the significant reductions in the Lm and DI values (Treatment 2 vs. Treatment 3; P 5 0.0017 and P 5 0.0011, respectively). The administration of CAM at doses of 50 mg/kg for 3 months significantly ameliorated the increase in the DI (Treatment 2 vs. Treatment 4; P 5 0.0114), whereas the administration of 50 mg/kg of CAM in the therapeutic protocol tended to decrease the Lm, although a significant difference was not reached (Treatment 2 5 38.4 6 1.2 ; Treatment 4 5 35.6 6 1.2; P 5 0.14). Treatment with 100 mg/kg of CAM in the therapeutic protocol attenuated the emphysema evoked by cigarette smoke, as demonstrated by a significant decrease in the Lm by 86% (P 5 0.0037) and in the DI by 87% (P 5 0.0004). Smoking cessation for 3 months resulted in reductions in air space enlargement and lung destruction compared with 6 months of smoke exposure; however, the DI did not recover to the level of the non-smokeexposed group (Treatment 6 in Table 2 ).
In the second experiment, we observed a 2.5-fold increase in the number of macrophages in BALF samples obtained from mice after long-term smoke exposure (Treatment 2 in Figure 3 ; P , 0.001). In contrast, CAM treatment at doses of 50 mg/kg in the preventive protocol or at doses of 100 mg/kg in the therapeutic protocol inhibited macrophage accumulation. The administration of CAM at doses of 50 mg/kg in the preventive between non-smoke-exposed mice and mice exposed to smoke for 1 week or 1, 3, or 6 months. Cells were isolated from bronchoalveolar lavage fluid (BALF) and subjected to cytospinning to determine the differential cell counts. The total cell numbers of macrophages in nonsmoke-exposed mice (open boxes) and in smoke-exposed mice (closed boxes) are shown. **P , 0.01, ***P , 0.001; significant difference compared with non-smoke-exposed treatment (Student t test). protocol (Treatment 3 in Figure 3 ) significantly reduced the number of macrophages in the BALF samples (P , 0.01). Treatment with CAM at 100 mg/kg during the second half of a 6-month exposure period (Treatment 5) or smoking cessation for 3 months (Treatment 6) reduced macrophage recruitment to the baseline level, despite the significant increase in the number of cells in the BALF samples after 3 months of exposure (see Figure 2) . As in the case of macrophages, CAM treatment tended to cause a decrease in the recruitment of neutrophils into the BALF samples ( Figure 3B ), although the neutrophil counts were not significantly different. Together, our data indicate that CAM suppresses the progression of lung inflammation and prevents emphysema evoked by cigarette smoke. We were unable to identify any microorganisms in the mice or infections in the mouse colony, suggesting that the effect of CAM was independent of its antibiotic activity.
Lung Compliance Assessment
An increase in lung compliance was observed in the smokeexposed mice, consistent with their emphysema. Six months of smoke exposure (Treatment 2 in Figure 4 ) significantly enhanced lung compliance by 11% compared with the control non-smokeexposed mice, as demonstrated using a FlexiVent (Treatment 1 in Figure 4 ; P , 0.05). The administration of CAM at a dose of 50 mg/kg for 6 months prevented the increase in lung compliance (Treatment 2 versus 3 in Figure 4 ; P , 0.05). Three months of smoking cessation and CAM treatment at doses of 50 or 100 mg/ kg for 3 months in the therapeutic protocol (Treatments 4 and 5) partially inhibited the increase in lung compliance compared with 6 months of smoke exposure (Treatment 2), but the difference was not statistically significant.
Effect of CAM on Macrophage Accumulation in the Lung Parenchyma in Response to Cigarette Smoke
Macrophages in the lung parenchyma are positioned to be directly involved in the degradation of extracellular matrix components and enhance emphysema by producing MMP-12 and other proteases (3, 22) . Therefore, we counted the F4/80-positive cells, which represent macrophages, in the lung parenchyma. Six months of smoke exposure increased the number of F4/80-positive macrophages by ninefold compared with the non-smoke-exposed group as shown using an immunohistochemical staining method (Treatment 1 vs. 2 in Figure 5 ; P , 0.001). On the other hand, the administration of CAM in the preventive and therapeutic protocols as well as smoking cessation for 3 months significantly decreased the number of F4/80-positive cells (Treatment 2 vs. 3, 4, 5, or 6 in Figure 5 ; all P , 0.01 or 0.001). These data demonstrate that CAM prevents the accumulation of macrophages in the lung parenchyma in response to cigarette smoke.
Direct Effect of CAM on Macrophage Activation by TNF-a
Inflammatory cytokines such as TNF-a activate macrophages and augment emphysema by enhancing the production of MMPs and other inflammatory molecules. We investigated whether CAM at a concentration equivalent to that achieved Macrophage and neutrophil counts in bronchoalveolar lavage fluid (BALF) after 6 months of smoke exposure. Cells were isolated from BALF and subjected to cytospinning to determine the differential cell counts. Treatment 1: Non-smoke-exposed for 6 months. Treatment 2: exposed to cigarette smoke for 6 months (SM). Treatment 3: SM treated with clarithromycin (CAM) at 50 mg/kg for 6 months. Treatment 4: SM treated with CAM at 50 mg/kg during the second half of the 6-month smoke-exposure period. Treatment 5: SM treated with CAM at 100 mg/kg during the second half of the 6-month smoke-exposure period. Treatment 6: exposed to cigarette smoke for 3 months and smoking cessation for 3 months. The total cell numbers of macrophages (A) and neutrophils (B) are shown. The bars represent the mean 6 SEM in each treatment. ***P , 0.001; significant difference compared with non-smoke-exposed treatment (Student t test). † † P , 0.01; significant difference compared with smoke-exposed treatment (Student t test). $$ P , 0.001; significant difference compared with smoke-exposed treatment (multiple comparison Dunnett test). The neutrophil counts were not significantly different. Figure 4 . Lung compliance assessment after smoke exposure. After 6 months of smoke exposure, a lung compliance assessment was performed using a FlexiVent. Each treatment and the number of mice are shown in the legends of Table 2 and Figure 3 . The bars represent the mean lung compliance 6 SEM for each treatment. *P , 0.05; significant difference compared with non-smoke-exposed treatment (Student t test). † P , 0.05; significant difference compared with smoke-exposed treatment (Student t test).
clinically could directly suppress the activation of macrophages by TNF-a. The maximum drug concentration (C max ) values for CAM in mouse lung tissue after a single oral administration at doses of 50 or 100 mg/kg reached 40.0 mg/g of tissue (5.3 mM) and 90.7 mg/g of tissue (12.1 mM), respectively. We regarded MMP-9 induction as an index of inflammatory activation in macrophages in this study. Therefore, we treated mouse peritoneal macrophages with 1.25 to 20 mM of CAM and observed the expression of MMP-9 mRNA stimulated by TNF-a. Stimulation with 25 ng/mL of TNF-a increased the relative expression of MMP-9 mRNA in the mouse macrophages by fourfold, whereas CAM at doses of 5 and 20 mM inhibited the accumulation of MMP-9 mRNA in a dose-dependent manner by 30 and 50%, respectively ( Figure 6 ). These data suggest that the administration of CAM at clinically achievable levels might directly modulate inflammatory activation induced by TNF-a in macrophages.
DISCUSSION
Drug treatment for COPD remains a significant challenge and an unmet need. COPD is a chronic inflammatory disease characterized by a rapid decline in lung function as a result of emphysema and small airway obstruction. The inflammation underlying COPD differs from that of asthma in its response to glucocorticosteroids. Phosphodiesterase type 4 inhibitors, such as cilomilast and roflumilast, are novel antiinflammatory drugs that have recently been show to be effective clinically in patients with COPD, although further conclusions regarding the therapeutic values of these compounds await the outcome of longer-term clinical trials (12) . Low-dose, long-term, 14-membered ring macrolide therapy, such as the use of CAM or erythromycin, has been established for the treatment of diffuse panbronchiolitis. These drugs are effective via antiinflammatory mechanisms other than antibacterial activity (21) . In addition, erythromycin can lower the frequency and risk of exacerbation in patients with COPD by preventing Mycoplasma infection (24) . However, the full effects of macrolides on emphysema evoked by cigarette smoke remain uncertain.
In this study, we demonstrated that oral CAM treatment decreased airspace enlargement (Lm) and the destruction of alveolar walls (DI) while preventing an increase in lung com- Table 2 . The data represent the F4/80-positive cell (macrophage) number 6 SEM. ***P , 0.001; significant difference compared with non-smoke-exposed treatment. † † P , 0.01; significant difference compared with smoke-exposed treatment (Student t test). $$$ P , 0.001; significant difference compared with smoke-exposed treatment (multiple comparison Dunnett test). Scale bars, 25 mm. pliance and impairing the accumulation of inflammatory cells in mice exposed to cigarette smoke for 6 months. CAM significantly prevented the enlargement of the lung parenchyma and the destruction of the alveolar walls even when the mice were treated with CAM after the onset of lung inflammation. In the therapeutic protocol, the DI values demonstrated that CAM slowed and stabilized the ongoing process of inflammation more effectively than smoking cessation in smoke-exposed mice. These data suggest that treatment with CAM may add clinical benefit to intervention programs for smoking cessation. The pharmacokinetic parameters for CAM in mice after the oral administration of 100 mg/kg were comparable to those in humans receiving low-dose CAM treatment for diffuse panbronchiolitis. Among the 14-membered ring macrolides, CAM accumulates in lung tissue and alveolar macrophages at a relatively high level (25, 26) and is expected to affect a variety of respiratory diseases as a result of its high affinity to lung tissue.
The beneficial effects of CAM on emphysema are considered to be due to an antiinflammatory mechanism rather than an antiinfective mechanism because this model was not associated with infection. We have not identified the molecular targets to which CAM directly binds, and the precise molecular mechanism of CAM's effects on smoke-induced emphysema remains unclear. The histologic data obtained in the present study indicate that CAM dramatically impairs the accumulation of macrophages and the destruction of alveolar walls. These data suggest that the pharmacologic action of CAM may involve the suppression of chemotactic factor production and/or the inactivation of proteases, including MMPs, elastases, and cathepsins, that promote the destruction of alveolar walls.
The accumulation of macrophages and monocytes in COPD lung lesions reportedly involves the production of chemotactic factors, such as chemokines (e.g., IL-8, MCP-1), and adhesion molecules, such as ICAM-1. Additionally, inflammatory cytokines augment the accumulation of macrophages in the lung parenchyma. Several studies have suggested that one of potential mechanisms of CAM in emphysema may be reduction in the accumulation of macrophages by suppressing inflammatory chemokines and cytokines.
Fourteen-membered ring macrolides have been reported to suppress the expression and release of IL-6, IL-8, and ICAM-1 in human bronchial epithelial cells, thereby impairing chronic inflammation (18) (19) (20) . CAM attenuates the expression of the mucin gene MUC5AC, which has been implicated in mucus secretion (27) . Macrolides have also been reported to suppress the expression and release of TNF-a and IL-1b in human monocytes and murine macrophages (28, 29) .
CAM reportedly attenuates the expression of lung inflammatory molecules at the mRNA transcription level by preventing the activation of transcription factor NF-kB and AP-1 (30) (31) (32) , which are related to augmentation of lung inflammation.
Macrophages are considered to have a crucial role in the pathophysiology of COPD. Differentiated macrophages in the lung parenchyma are thought to be involved directly in the degradation of extracellular matrix components through the production of MMP-12 and other proteases, to enhance the cigarette smoke-induced destruction of alveolar walls, and to augment emphysema. We demonstrated that CAM prevented the accumulation of macrophages in lung parenchyma and in BALF, suggesting a reduction in the overall elastolysis activity of MMP-12 and other proteases in lung tissue treated with CAM compared with vehicle treatment, but we did not observe the enzyme inhibitory activities of proteases, such as MMPs and elastase, at a concentration of 20 mM, which is comparable to the drug concentration in the lung (data not shown). Recent observations have shown that the augmented production of proteolytically generated elastin fragments (EFs) promotes the recruitment of monocytes from the circulation into lung tissues in response to cigarette smoke (33) . The study demonstrated that EFs are required for the accumulation of macrophages and airspace enlargement in the lung in this mouse model. The targeted disruption of MMP-12 reduced the accumulation of macrophages in the lung by abrogating the production of EFs and impaired emphysema. MMP-12 expression in macrophages is regulated by inflammatory cytokines such as GM-CSF and TNF-a in the lung (34, 35) . CAM is reported to attenuate the expression of these cytokines in bronchial epithelial cells and macrophages and may indirectly regulate the expression of MMP-12, although we did not confirm the direct inhibition of MMP-12 production by CAM in mice macrophages in an in vitro study.
In addition to MMP-12, the TNF-a signaling cascade has a pivotal role in augmenting lung inflammation and the development of emphysema. Previous work demonstrated that the targeted disruption of TNF-a receptors reduced cigarette smoke-induced emphysema (36) . We documented that CAM at clinically comparable concentrations directly suppressed the activation of macrophages by TNF-a, including the inhibition of MMP-9 mRNA expression in mouse macrophages. TNF-ainduced MMP-9 expression involves various signaling molecules, such as transcription factor NF-kB, p42/p44 MAPK, p38 MAPK, and JNK (37, 38) . The elucidation of the downstream molecular mechanism by which CAM suppresses the accumulation of macrophages in lung tissue and modulates chronic lung inflammation requires further investigation.
The in vitro data demonstrated that the antiinflammatory activity evoked by CAM at a clinically achievable concentration seems to be rather moderate compared with the activities of other antiinflammatory compounds, such as chemokine receptor antagonists and selective inhibitors of signaling molecules. This property of CAM may be responsible for the relatively narrow dose response observed in the in vivo study. However, our observations suggested that the moderate antiinflammatory activity of CAM has sufficient benefit on low-grade chronic lung inflammatory diseases such as COPD when administered as long-term treatment.
A double-blind, randomized, placebo-controlled trial of CAM in patients with severe refractory asthma showed that 8 weeks of CAM therapy significantly reduced the concentrations of MMP-9 and IL-8 as well as the neutrophil counts in sputum samples, thereby improving the patients' quality of life (39) . These data suggest that CAM might impair chronic inflammation in human lung tissue without causing significant adverse events. In contrast, oral CAM at a dose of 500 mg/d for 3 months had no significant effect on the sputum neutrophil count or the cytokine levels in patients with moderate-to-severe, stable COPD (40) . However, CAM did cause a small reduction in the neutrophil differential and in neutrophil chemotaxis. An evaluation of the therapeutic efficacy of CAM in COPD requires further clinical investigations involving long-term clinical testing.
Low-dose, long-term macrolide treatment may encourage the growth of organisms resistant to antibiotics. A recent study showed that a new derivative of erythromycin without antibiotic activity, EM703, demonstrated antiinflammatory and anti-fibrotic activities in a bleomycin-induced lung injury model (41) , suggesting that the structure-activity relationship of macrolides may differ in their antibiotic and antiinflammatory activities against emphysema. In addition, the possible mechanism by which CAM prevents emphysema may involve other inflammatory molecules, such as cytokines, chemokines, and signaling molecules. Further studies are needed to determine the mechanism underlying the antiinflammatory action of CAM in emphysema.
In conclusion, this study demonstrated that clinically achievable levels of CAM prevent or ameliorate emphysema induced by cigarette smoke in mice in a manner that is independent of CAM's antibiotic effects. From a practical standpoint, this study raises the possibility that low-dose, long-term CAM treatment might provide a new therapeutic strategy for patients with pulmonary emphysema, a main component of COPD.
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